

Company Fact Sheet

- Profile:** Proventys is a healthcare technology company developing advanced decision support solutions that help clinicians optimize treatment decisions at the point of care in oncology, cardiology and other areas. The Company has an exclusive relationship with the National Comprehensive Cancer Network (NCCN) to develop and commercialize the Proventys CDS Oncology™ system, an innovative decision support platform that dynamically renders the NCCN Guidelines™ and prompts clinicians with recommended treatment options based on individual patient characteristics. The Company also has developed the Proventys PDx Oncology™ system, a novel medical device that delivers software-based predictive tests targeting specific clinical events. Its lead predictive test, the FN PDx™, assesses an adult cancer patient's individualized risk of febrile neutropenia (FN), a serious adverse event of chemotherapy. The product is under review by the FDA (de novo) and not available for sale in the United States.
- Mission:** Proventys sees a future where healthcare evolves from a reactive system, in which one size fits all, to a prospective approach that enables individuals and their providers to prevent, minimize and treat illness on a personalized basis. We intend to play a role in this transformation by aligning the interests of patients, providers and payers and offering solutions that personalize care and improve outcomes.
- History:** Based in Newton, Mass., Proventys was founded in 2005 by Dr. Ralph Snyderman, Chancellor Emeritus of Duke University and a national leader in the field of personalized medicine.
- Ownership:** Privately held
- Financing:** Proventys is backed by Burrill & Company, a leading life sciences venture capital and private equity firm based in San Francisco, Calif.
- Key Collaborators:** Proventys has an exclusive collaboration with the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, dedicated to improving the quality and effectiveness of care provided to patients with cancer. The Company also has a strategic partnership with McKesson Provider Technologies focused on developing and marketing predictive technologies in cardiology and other areas in the hospital setting.



Management Team: Timothy Thompson, President & CEO

Surya Singh, MD, Chief Medical Officer & Vice President of Clinical Development

Richard Morello, Vice President, Strategy and Market Development

Dennis Reilly, Vice President, Finance & Administration

Board of Directors:

Ralph Snyderman, MD, Founder of Proventys, Inc.; Chancellor Emeritus, Duke University; James B. Duke Professor of Medicine at Duke University

G. Steven Burrill, Chief Executive Officer, Burrill & Company

David M. Lawrence, MD, Former CEO and Chairman of the Boards of Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals

Marc Owen, Executive Vice President, Corporate Strategy and Business Development, McKesson Corporation

Franklyn Prendergast, MD, Director for the Mayo Clinic Center for Individualized Medicine

Offices:

Headquarters

275 Grove Street, Suite 2-310
Newton, MA 02466

Phone: 866.963.2335

Fax: 617.527.0138

Website:

www.proventys.com

Contacts:

Rick Morello
Proventys
617.527.1769
rick.morello@proventys.com

Jackie Hanley
Racepoint Group
781.487.4625
jhanley@racepointgroup.com

###